International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Boehringer Ingelheim announced that the United States Food and Drug Administration (FDA) granted Break Through Therapy Designation (BTD) to spesolimab (marketed as SPEVIGO®), an investigational treatment aimed at preventing flares in teenagers and adults suffering from generalized pustular psoriasis (GPP). Spesolimab has been granted approval by regulatory agencies for the treatment of GPP flares in nearly 40 countries.


Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.